InCarda Therapeutics, Inc.

By most measures, 2022 was a good year for venture capital funds that invest in health care companies, with the total amount of capital raised last year coming in second only to the record-setting fig

Theravance Biopharma Inc. will eliminate debt from its balance sheet and improve its cash balance through the sale of its interest in Theravance Respiratory Company LLC (TRC) – representing an 85% sh

Privately held InCarda Therapeutics, Inc. unveiled a $30m series C financing on 21 October that it says can get it much of the way toward approval of an inhaled anti-arrhythmic to quickly stop acute

Biomatics Capital Partners closed its second fund focused on breakthrough science and technology in health care, bringing in $300m to fund the development of therapeutics, diagnostics, research and de